The initial episode Clinical Trials and COVID-19: An Insider’s Perspective focuses on how the coronavirus pandemic has radically (and no doubt permanently) changed the world of clinical trials. Nicholas Borys, MD, Chief Medical Officer at Celsion Corporation discusses with podcast co-hosts Bob Karczewski and Steve Nothel how Celsion—which is concluding Phase 3 clinical studies for primary liver cancer and conducting Phase 2 clinical studies for ovarian cancer—has adjusted to the new normal to develop innovative methods to conduct trials without jeopardizing patient safety. Remarkably, one of the main centers for the liver cancer study was about 80 miles from Wuhan, China, the pandemic’s epicenter, making Borys’ retelling of this story a must-listen.